Tuesday, May 1, 2012

More Evidence Bilingualism Aids Thinking Skills - Health News - Health.com

More Evidence Bilingualism Aids Thinking Skills - Health News - Health.com

More Evidence Bilingualism Aids Thinking Skills

April 30, 2012


MONDAY, April 30 (HealthDay News) — People who speak two languages have enhanced hearing processing, which improves their attention and memory skills, a new, small study says.
Northwestern University researchers recorded the brainstem responses in 23 English- and-Spanish speaking teens and 25 English-only speaking teens as they heard speech sounds in two conditions.

Under quiet conditions, both groups had similar results. But when there was background noise, the bilingual teens’ brains did better at detecting speech sounds.
The findings show that being bilingual changes how the nervous system responds to sound, according to the researchers.
“People do crossword puzzles and other activities to keep their minds sharp,” study co-author Viorica Marian, a bilingualism expert and associate professor of communication sciences, said in a university news release.
“But the advantages we’ve discovered in dual language speakers come automatically simply from knowing and using two languages. It seems that the benefits of bilingualism are particularly powerful and broad, and include attention, inhibition and encoding of sound,” she explained.
The study appears April 30 in the Proceedings of the National Academy of Sciences.
“Bilinguals are natural jugglers,” Marian said. “The bilingual juggles linguistic input and, it appears, automatically pays greater attention to relevant versus irrelevant sounds. Rather than promoting linguistic confusion, bilingualism promotes improved ‘inhibitory control,’ or the ability to pick out relevant speech sounds and ignore others.”
More information
The American Speech-Language-Hearing Association has more about the benefits of being bilingual.
– Robert Preidt
SOURCE: Northwestern University, news release, April 30, 2012
Last Updated: April 30, 2012
Copyright © 2012 HealthDay. All rights reserved.
*

Being Bilingual Brings Mental Health Benefits

American Psychology–Law Society - Wikipedia, the free encyclopedia

American Psychology–Law Society - Wikipedia, the free encyclopedia

American Psychology–Law Society
From Wikipedia, the free encyclopedia
Jump to: navigation, search
The American Psychology-Law Society (AP-LS) is an academic society for legal and forensic psychologists, as well as general psychologists who are interested in the application of psychology to the law. AP-LS serves as Division 41 of the American Psychological Association and publishes the academic journal Law and Human Behavior.

[edit] External links

Law and Human Behavior - Wikipedia, the free encyclopedia

Law and Human Behavior - Wikipedia, the free encyclopedia

Law and Human Behavior
From Wikipedia, the free encyclopedia
Jump to: navigation, search
Law and Human Behavior
Law and Human Behavior
DisciplineLegal psychology, forensic psychology
LanguageEnglish
Edited byMargaret Bull Kovera
Publication details
PublisherAmerican Psychological Association
Publication history1977-present
FrequencyBimonthly
Impact factor
(2010)
2.268
Indexing
ISSN0147-7307 (print)
1573-661X (web)
LCCN77641812
CODENLHBEDM
OCLC number03173559
Links
Law and Human Behavior is a bimonthly academic journal published by the American Psychology–Law Society. It publishes original empirical papers, reviews, and meta-analyses on how the law, legal system, and legal process relate to human behavior, particularly legal psychology and forensic psychology.[1] The current editor-in-chief is Margaret Bull Kovera (John Jay College of Criminal Justice). Past editors have been Brian Cutler (University of Ontario Institute of Technology), Richard Weiner (University of Nebraska), Ronald Roesch (Simon Fraser University), Michael J. Saks (Arizona State University), and Bruce Sales (University of Arizona).

[edit] Abstracting and indexing

The journal is abstracted and indexed by MEDLINE/PubMed and the Social Science Citation Index. According to the Journal Citation Reports, the journal has a 2010 impact factor of 2.268, ranking it 7th out of 58 journals in the category "Psychology, Social"[2] and 13th out of 133 journals in the category "Law".[3]

[edit] References

  1. ^ "Law and Human Behavior". American Psychological Association. January 3 2012. http://www.apa.org/pubs/journals/lhb/index.aspx. Retrieved 2012-01-03.
  2. ^ "Journals Ranked by Impact: Psychology, Social". 2010 Journal Citation Reports. Web of Science (Social Sciences ed.). Thomson Reuters. 2012.
  3. ^ "Journals Ranked by Impact: Law". 2010 Journal Citation Reports. Web of Science (Social Sciences ed.). Thomson Reuters. 2012.

[edit] External links

Am I a Dangerous Man?

Am I a Dangerous Man?



Am I a Dangerous Man?

Definitive Study Rejects the Diagnosis of “Psychosis Risk” and Finds No Treatment Benefit - Psychiatric Times

Definitive Study Rejects the Diagnosis of “Psychosis Risk” and Finds No Treatment Benefit - Psychiatric Times


Definitive Study Rejects the Diagnosis of “Psychosis Risk” and Finds No Treatment Benefit

By Allen Frances, MD |April 16, 2012


The sad truth is that most clinical research has absolutely no effect on clinical practice—rarely does a study impact how we diagnose and treat patients. A paper by Morrison and colleagues1 in the British Medical Journal is that rare exception. For the pleasure of reading it, see http://www.bmj.com/content/344/bmj.e2233.
In this one beautiful study, the authors have succeeded in definitively answering two of the most timely and consequential questions facing psychiatry today: (1) Is it a good idea to include a “psychosis risk syndrome” in DSM 5? (2) Can early treatment programs prevent psychosis? The answers to both questions are conclusively and emphatically—No.
First off, the study proves that we don't yet have the basic diagnostic tools needed to build a preventive psychiatry. Fundamental to any meaningful prevention program is the accurate identification of those who are really at risk. This study clearly demonstrates the impossibility of predicting who is (and who is not) likely to become psychotic. It is striking that only 8% of so called “ultra high risk” patients actually go on to have a psychotic episode? The unacceptably high false-positive rate means that more than 9 of 10 people entered into a psychosis prevention program will be misidentified and told they are at risk (or even worse “ultra high risk”) for eventually becoming psychotic—when quite clearly they are not. There can be no justification for burdening young people with such unnecessary stigma and worries, reduced ambitions, and the risk of receiving potentially dangerous antipsychotic drugs. If they have problems that need addressing, these should be addressed, but not under the misleading and pejorative auspice of being at “ultra high risk.”
The authors follow their findings to the by now obvious conclusion that “psychosis risk syndrome” is still in its early research phase of development and makes no sense as an official category for DSM-5. Their powerful data support the almost unanimous opposition of the leading researchers on psychosis risk—including most notably the pioneers in the field, Patrick McGorry and Alison Yung. It is puzzling that DSM-5 persists in offering a suggestion so far out of touch with current clinical reality.
The treatment results are even more important and should discourage all unrealistic expectations that early and intense intervention can prevent psychosis. Those who received the preventive intervention were just as likely to become psychotic as those who did not. The conclusion is inescapable—prevention of psychosis is a wonderful but elusive goal, one that we cannot now achieve. We are still in the early stages of prevention research and the findings so far are not encouraging. With such low rates of conversion to psychosis, it seems unlikely that a treatment effect will ever be demonstrated.
This one excellent study has killed two birds with one stone. It is a clear caution against the DSM-5 proposal for a psychosis risk syndrome and it should temper enthusiasm for rushing ahead with “ultra high risk” prevention programs. It does the wonderful cause of prevention no good to prematurely set impossible tasks that it cannot yet accomplish. The research foundation must be much more developed before psychosis prevention will be ready for the real world.
Reference
1. Morrison AP, French P, Stewart SL, et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ. 2012;344:e2233. doi: 10.1136/bmj.e2233.

Mike Nova: The Health Of Nations

Mike Nova: The Health Of Nations


The idea of social justice is as old as are the ubiquitous and blatant practices of social injustice, first of all enslavement in its various forms and exploitation, on which "The Wealth Of Nations" was built. The 20th century Marxism seems to have combined both seamlessly.
Today we see more and more that "wealth of nations" depends to a large degree on "health of nations", namely, not only the conditions of their respective health services but their just (and therefore economically efficient) social and political order. The broad and universal concept of health with its notions of normal and abnormal social functioning can and should be applied to large social groups and systems, extending from the traditional notions of individual and small groups (family, industrial groups) to social health or socio-political pathology of countries and cultures (e.g. "failed states").


References and Links

Social class in the United States - From Wikipedia, the free encyclopedia:
Social class in the United States is a controversial issue, having many competing definitions, models, and even disagreements over its very existence.[1] Many Americans believe in a simple three-class model that includes the "rich", the "middle class", and the "poor". More complex models that have been proposed describe as many as a dozen class levels;[2][3] while still others deny the very existence, in the European sense, of "social class" in American society.[4] Most definitions of class structure group people according to wealth, income, education, type of occupation, and membership in a specific subculture or social network.
Sociologists Dennis Gilbert, William Thompson, Joseph Hickey, and James Henslin have proposed class systems with six distinct social classes. These class models feature an upper or capitalist class consisting of the rich and powerful, an upper middle class consisting of highly educated and affluent professionals, a middle class consisting of college-educated individuals employed in white-collar industries, a lower middle class, a working class constituted by clerical and blue collar workers whose work is highly routinized, and a lower class divided between the working poor and the unemployed underclass.[2][5][6]
A monument to the working and supporting classes along Market Street in the heart of San Francisco's Financial District

Mike Nova: Individual, group and social psychopathology can be viewed and conceptualised on the same biopsychosocial continuum. "Erich Fromm proposed that, not just individuals, but entire societies "may be lacking in sanity" - Sanity - Wikipedia, the free encyclopedia

Mike Nova: Individual, group and social psychopathology (and "normality") can be viewed and conceptualised on the same biopsychosocial continuum.

References and links:

biopsychosocial continuum - Google Search


Biopsychosocial model - From Wikipedia, the free encyclopedia

Sanity - Wikipedia, the free encyclopedia

In The Sane Society, published in 1955, psychologist Erich Fromm proposed that, not just individuals, but entire societies "may be lacking in sanity". Fromm argued that one of the most deceptive features of social life involves "consensual validation."[3]:
It is naively assumed that the fact that the majority of people share certain ideas or feelings proves the validity of these ideas and feelings. Nothing is further from the truth... Just as there is a folie à deux there is a folie à millions. The fact that millions of people share the same vices does not make these vices virtues, the fact that they share so many errors does not make the errors to be truths, and the fact that millions of people share the same form of mental pathology does not make these people sane.[4]

Fromm, Erich. The Sane Society, Routledge, 1955, pp.14–15.

The subject of Industry Ties of DSM Workers - PsychiatryOnline | Psychiatric News | News Article

The subject of Industry Ties of DSM Workers


PsychiatryOnline | Psychiatric News | News Article

Psychiatric News |
Volume 47 Number 8 page 1a-14
American Psychiatric Association
Professional News
Article Misrepresents Industry Ties of DSM Workers
Mark Moran
More than 70 percent of DSM-5 Task Force and work group members now have no ties to industry.
Abstract Teaser
An article in the online journal Public Library of Science (PLoS) has misrepresented facts about conflicts of interest among members of the DSM-5 Task Force and work groups, according to APA.
And it ignored the extent to which industry influence has been eliminated or greatly reduced because of strict financial disclosure requirements mandated by APA.
In a statement, APA President John Oldham, M.D., said the article, written by Lisa Cosgrove, Ph.D., and Sheldon Krimsky, Ph.D., “does not take into account the level to which DSM-5 Task Force and work group members have minimized or divested themselves from relationships with the pharmaceutical industry.”
Cosgrove is a research lab fellow at the Edmond J. Safra Center for Ethics at Harvard University. Krimsky is an adjunct professor in the Department of Public Health and Family Medicine at the Tufts School of Medicine
The article, “A Comparison of DSM-IV and DSM-5 Panel Members’ Financial Associations With Industry: A Pernicious Problem Persists,” states that APA’s financial disclosure policy for DSM-5 has not resulted in a reduction of conflicts of interest and concludes that “transparency alone cannot mitigate the potential for bias and is an insufficient solution for protecting the integrity of the revision process.”
The article appeared online March 13.
But Oldham said the authors of the article drew comparisons to DSM-IV—for which there were not the stringent requirements for financial disclosure that exist for DSM-5 contributors—to suggest erroneously that there has been an increase in conflicts of interest.
“[S]ince there were no disclosure requirements for journals, symposia, or the DSM-IV Task Force at the time of the 1994 release of DSM-IV, Cosgrove and Krimsky’s comparison of DSM-IV and DSM-5 Task Force and work group members is not valid,” Oldham said. “In assembling DSM-5 ’s Task Force and work groups, APA’s Board of Trustees developed an extensive process of written disclosure of potential conflicts of interest. These disclosures are required of all professionals who participate in the development of DSM-5. An independent APA committee reviews these disclosure documents, which are updated annually or whenever a member’s financial interests change.”
Oldham’s response noted that currently, 72 percent of the 153 members reported no relationships with the pharmaceutical industry during the previous year. Moreover, the scope of the relationships reported by the remaining 29 percent varies:
  • 12 percent reported grant support only, including funding or receipt of medications for clinical trial research.
  • 10 percent reported paid consultations including advice on the development of new compounds to improve treatments.
  • 7 percent reported receiving honoraria.
These figures contradicted those cited by Cosgrove and Krimsky, who wrote, “Currently, 69 percent of the DSM-5 task force members report having ties to the pharmaceutical industry.”
They went on to add, “This represents a relative increase of 21 percent over the proportion of DSM-IV Task Force members with such ties (57 percent of DSM-IV task force members had ties).”
When queried for a response to APA’s challenge to the PLoS article, Cosgrove said their data for DSM-IV were “based on objective information we obtained from published sources since DSM did not disclose at that time the financial interests of panel members.”
She added, “We used the same methodology in the current study although the sources of information were different because DSM-5 did a lot of work for us by disclosing the financial ties.”
With regard to the apparent discrepancy in reported industry ties, Cosgrove said in her response that the figures she derived for the DSM-5 group include the full three-year period prior to each person’s nomination to the task force or work group, as was required for participation in DSM-5.
She added, “It is important in reporting financial interests that one chooses a time period prior to the publication of the document. Thus, in order to compare the commercial ties of the DSM-IV and DSM-5 groups, we relied on the best available data for each group: published disclosures (for example, in peer-reviewed medical journals) of financial ties for DSM-IV and the disclosure forms for the DSM-5 groups.”
But Darrel Regier, M.D., M.P.H, APA’s director of research, said that using the entire three-year reporting data and presenting the data as current ignores the degree to which DSM-5 reporting requirements have resulted in minimization or divestment of industry ties over time.
“As documented in their previous publications, these authors take the position that if there was ever any kind of relationship with the pharmaceutical industry, the clinician should be excluded from DSM-5 participation—an extreme position with which we disagree,” Regier told Psychiatric News. “As a result, they counted all disclosures for all years that were posted for DSM-IV Task Force members after 1994 publication of DSM-IV and contrasted that with DSM-5 Task Force member disclosures for three years prior to their appointment—without recognizing the substantial decrease in member affiliations as the DSM process progressed over five years.”
Regier added, “It is clear that there has been a sea change in how academic investigators related to industry over the past seven years since 2005—three years before the work group members were reviewed for their 2008 appointments to the DSM-5 Task Force. A good number of investigators were providing lectures at industry-sponsored symposia at the APA [annual meeting] and other meetings from 2005 to 2007, when those who were invited to participate in DSM-5 agreed to limit and often end such relationships.
“The use of the words ‘a pernicious problem persists’ in the headline is unfortunate and highly inaccurate,” Regier said. “The implication is that the relationships continue to exist as previously, when in fact there has been a marked drop in industry relationships—which the authors fail to recognize or acknowledge.”inline-graphic-1.gif
“A Comparison of DSM-IV and DSM-5 Panel Members’ Financial Associations With Industry: A Pernicious Problem Persists” is posted at www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001190.

Being Bilingual Brings Mental Health Benefits

Psychiatric News Alert: Being Bilingual Brings Mental Health Benefits
Monday, April 30, 2012

Being Bilingual Brings Mental Health Benefits 

Individuals who are bilingual appear to have superior sound-processing skills, Northwestern University researchers reported today in the Proceedings of the National Academy of Sciences. This finding suggests that bilingual individuals might possess an enhanced ability to pay attention, the researchers believe.

Being able to speak two languages likewise seems to reduce, in children, negative internalizing states such as anxiety, loneliness, and poor self-esteem, and negative externalizing behaviors such as arguing, fighting, or acting impulsively, other researchers have found. The reason, they hypothesized, may be because bilingual youngsters understand two cultures, and this understanding in turn helps them appreciate diversity and get along with their peers and teachers.

More information about this study of bilingual children can be found in Psychiatric News.

More Evidence Bilingualism Aids Thinking Skills - ...

*
 

The British Journal of Psychiatry current issue Review

Google Reader - Mike Nova's starred items

The British Journal of Psychiatry current issue Review

 

via The British Journal of Psychiatry current issue by Wilson, S., Argyropoulos, S. on 4/2/12
Recent sleep research has highlighted two specific anomalies in schizophrenia that have a proven impact on cognition. One is an abnormality of circadian rhythm, reported in this journal in two separate studies over the past year, and the other is the finding in electroencephalograms of reduced sleep spindles.

via The British Journal of Psychiatry current issue by Borgwardt, S., Fusar-Poli, P. on 4/2/12
Psychiatric imaging needs to move away from simple investigations of the neurobiology underlying the early phases of schizophrenia to translate imaging findings in the clinical field, targeting clinical outcomes including transition, remission and response to preventive interventions.

via The British Journal of Psychiatry current issue by Peluso, M. J., Lewis, S. W., Barnes, T. R. E., Jones, P. B. on 5/1/12
Background
Second-generation antipsychotics have been thought to cause fewer extrapyramidal side-effects (EPS) than first-generation antipsychotics, but recent pragmatic trials have indicated equivalence.
Aims
To determine whether second-generation antipsychotics had better outcomes in terms of EPS than first-generation drugs.
Method
We conducted an intention-to-treat, secondary analysis of data from an earlier randomised controlled trial (n = 227). A clinically significant difference was defined as double or half the symptoms in groups prescribed first- v. second-generation antipsychotics, represented by odds ratios greater than 2.0 (indicating advantage for first-generation drugs) or less than 0.5 (indicating advantage for the newer drugs). We also examined EPS in terms of symptoms emergent at 12 weeks and 52 weeks, and symptoms that had resolved at these time points.
Results
At baseline those randomised to the first-generation antipsychotic group (n = 118) had similar EPS to the second-generation group (n = 109). Indications of resolved Parkinsonism (OR = 0.5) and akathisia (OR = 0.4) and increased tardive dyskinesia (OR = 2.2) in the second-generation drug group at 12 weeks were not statistically significant and the effects were not present by 52 weeks. Patients in the second-generation group were dramatically (30-fold) less likely to be prescribed adjunctive anticholinergic medication, despite equivalence in terms of EPS.
Conclusions
The expected improvement in EPS profiles for participants randomised to second-generation drugs was not found; the prognosis over 1 year of those in the first-generation arm was no worse in these terms. The place of careful prescription of first-generation drugs in contemporary practice remains to be defined, potentially improving clinical effectiveness and avoiding life-shortening metabolic disturbances in some patients currently treated with the narrow range of second-generation antipsychotics used in routine practice. This has educational implications because a generation of psychiatrists now has little or no experience with first-generation antipsychotic prescription.

via The British Journal of Psychiatry current issue by Nicholson, T. R. J., Ferdinando, S., Krishnaiah, R. B., Anhoury, S., Lennox, B. R., Mataix-Cols, D., Cleare, A., Veale, D. M., Drummond, L. M., Fineberg, N. A., Church, A. J., Giovannoni, G., Heyman, I. on 5/1/12
Background
Symptoms of obsessive–compulsive disorder (OCD) have been described in neuropsychiatric syndromes associated with streptococcal infections. It is proposed that antibodies raised against streptococcal proteins cross-react with neuronal proteins (antigens) in the brain, particularly in the basal ganglia, which is a brain region implicated in OCD pathogenesis.
Aims
To test the hypothesis that post-streptococcal autoimmunity, directed against neuronal antigens, may contribute to the pathogenesis of OCD in adults.
Method
Ninety-six participants with OCD were tested for the presence of anti-streptolysin-O titres (ASOT) and the presence of anti-basal ganglia antibodies (ABGA) in a cross-sectional study. The ABGA were tested for with western blots using three recombinant antigens; aldolase C, enolase and pyruvate kinase. The findings were compared with those in a control group of individuals with depression (n = 33) and schizophrenia (n = 17).
Results
Positivity for ABGA was observed in 19/96 (19.8%) participants with OCD compared with 2/50 (4%) of controls (Fisher’s exact test P = 0.012). The majority of positive OCD sera (13/19) had antibodies against the enolase antigen. No clinical variables were associated with ABGA positivity. Positivity for ASOT was not associated with ABGA positivity nor found at an increased incidence in participants with OCD compared with controls.
Conclusions
These findings support the hypothesis that central nervous system autoimmunity may have an aetiological role in some adults with OCD. Further study is required to examine whether the antibodies concerned are pathogenic and whether exposure to streptococcal infection in vulnerable individuals is a risk factor for the development of OCD.

via The British Journal of Psychiatry current issue by Chen, S.-J., Chao, Y.-L., Chen, C.-Y., Chang, C.-M., Wu, E. C.-H., Wu, C.-S., Yeh, H.-H., Chen, C.-H., Tsai, H.-J. on 5/1/12
Background
The association between autoimmune diseases and schizophrenia has rarely been systematically investigated.
Aims
To investigate the association between schizophrenia and a variety of autoimmune diseases and to explore possible gender variation in any such association.
Method
Taiwan’s National Health Insurance Research Database was used to identify 10 811 hospital in-patients with schizophrenia and 108 110 age-matched controls. Univariate and multiple logistic regression analyses were performed, separately, to evaluate the association between autoimmune diseases and schizophrenia. We applied the false discovery rate to correct for multiple testing.
Results
When compared with the control group, the in-patients with schizophrenia had an increased risk of Graves’ disease (odds ratio (OR) = 1.32, 95% CI 1.04–1.67), psoriasis (OR = 1.48, 95% CI 1.07–2.04), pernicious anaemia (OR = 1.71, 95% CI 1.04–2.80), celiac disease (OR = 2.43, 95% CI 1.12–5.27) and hypersensitivity vasculitis (OR = 5.00, 95% CI 1.64–15.26), whereas a reverse association with rheumatoid arthritis (OR = 0.52, 95% CI 0.35–0.76) was also observed. Gender-specific variation was found for Sjögren syndrome, hereditary haemolytic anaemia, myasthenia gravis, polymyalgia rheumatica and dermatomyositis.
Conclusions
Schizophrenia was associated with a greater variety of autoimmune diseases than was anticipated. Further investigation is needed to gain a better understanding of the aetiology of schizophrenia and autoimmune diseases.

Mike Nova's starred items

via The British Journal of Psychiatry current issue by Fazel, S., Seewald, K. on 5/1/12
Background
High levels of psychiatric morbidity in prisoners have been documented in many countries, but it is not known whether rates of mental illness have been increasing over time or whether the prevalence differs between low–middle-income countries compared with high-income ones.
Aims
To systematically review prevalence studies for psychotic illness and major depression in prisoners, provide summary estimates and investigate sources of heterogeneity between studies using meta-regression.
Method
Studies from 1966 to 2010 were identified using ten bibliographic indexes and reference lists. Inclusion criteria were unselected prison samples and that clinical examination or semi-structured instruments were used to make DSM or ICD diagnoses of the relevant disorders.
Results
We identified 109 samples including 33 588 prisoners in 24 countries. Data were meta-analysed using random-effects models, and we found a pooled prevalence of psychosis of 3.6% (95% CI 3.1–4.2) in male prisoners and 3.9% (95% CI 2.7–5.0) in female prisoners. There were high levels of heterogeneity, some of which was explained by studies in low–middle-income countries reporting higher prevalences of psychosis (5.5%, 95% CI 4.2–6.8; P = 0.035 on meta-regression). The pooled prevalence of major depression was 10.2% (95% CI 8.8–11.7) in male prisoners and 14.1% (95% CI 10.2–18.1) in female prisoners. The prevalence of these disorders did not appear to be increasing over time, apart from depression in the USA (P = 0.008).
Conclusions
High levels of psychiatric morbidity are consistently reported in prisoners from many countries over four decades. Further research is needed to confirm whether higher rates of mental illness are found in low- and middle-income nations, and examine trends over time within nations with large prison populations.

Current knowledge of the role of autoimmunity in the pathogenesis of the main psychiatric disorders is briefly outlined. The significance of immunological effects on synaptic transmission and associated neuropsychiatric syndromes is emphasised. Clinical psychiatrists are encouraged to keep abreast of developments in this increasingly important area.

International Perspectives on Mental Health - British Journal of Psychiatry - General Psychiatry News

Google Reader - General Psychiatry News


Cover
Full text
International Perspectives on Mental Health BJP May 2012 200:434;
 


International Perspectives on Mental Health
British Journal of Psychiatry
Ghodse's volume comprises articles commissioned for the journal International Psychiatry, and falls somewhere between a formal atlas and more informal internet sources. Articles are often written by senior figures in the field (and in some cases by the ...

Severe mental illness in 33 588 prisoners worldwide: systematic review and meta-regression analysis

Severe mental illness in 33 588 prisoners worldwide: systematic review and meta-regression analysis

  • Review article

  • Severe mental illness in 33 588 prisoners worldwide: systematic review and meta-regression analysis

    1. Katharina Seewald, Bsc
    + Author Affiliations
    1. Department of Psychiatry, University of Oxford, Warneford Hospital, UK
    2. Department of Psychiatry, University of Oxford, Warneford Hospital, UK and Department of Psychology, University of Konstanz, Germany
    1. Correspondence: Seena Fazel, University Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX, UK. Email: seena.fazel@psych.ox.ac.uk
    • Declaration of interest
      None.

    Abstract

    Background
    High levels of psychiatric morbidity in prisoners have been documented in many countries, but it is not known whether rates of mental illness have been increasing over time or whether the prevalence differs between low–middle-income countries compared with high-income ones.
    Aims
    To systematically review prevalence studies for psychotic illness and major depression in prisoners, provide summary estimates and investigate sources of heterogeneity between studies using meta-regression.
    Method
    Studies from 1966 to 2010 were identified using ten bibliographic indexes and reference lists. Inclusion criteria were unselected prison samples and that clinical examination or semi-structured instruments were used to make DSM or ICD diagnoses of the relevant disorders.
    Results
    We identified 109 samples including 33 588 prisoners in 24 countries. Data were meta-analysed using random-effects models, and we found a pooled prevalence of psychosis of 3.6% (95% CI 3.1–4.2) in male prisoners and 3.9% (95% CI 2.7–5.0) in female prisoners. There were high levels of heterogeneity, some of which was explained by studies in low–middle-income countries reporting higher prevalences of psychosis (5.5%, 95% CI 4.2–6.8; P = 0.035 on meta-regression). The pooled prevalence of major depression was 10.2% (95% CI 8.8–11.7) in male prisoners and 14.1% (95% CI 10.2–18.1) in female prisoners. The prevalence of these disorders did not appear to be increasing over time, apart from depression in the USA (P = 0.008).
    Conclusions
    High levels of psychiatric morbidity are consistently reported in prisoners from many countries over four decades. Further research is needed to confirm whether higher rates of mental illness are found in low- and middle-income nations, and examine trends over time within nations with large prison populations.

    Severe mental illness in 33 588 prisoners worldwide: systematic review and ...
    British Journal of Psychiatry
    Correspondence: Seena Fazel, University Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX, UK. Email: seena.fazel{at}psych.ox.ac.uk High levels of psychiatric morbidity in prisoners have been documented in many countries, but it is not known ...